Congenital primary aphakia

From WikiMD's WELLNESSPEDIA

Alternate names[edit]

Aphakia, congenital primary; CPA

Definition[edit]

Congenital primary aphakia (CPA) is a rare eye condition that is present at birth in which the lens is missing.

Cause[edit]

This condition is thought to result from an abnormality during the 4th or 5th week of fetal development, which prevents the formation of any lens structure in the eye. Mutations in the FOXE3 gene have been associated with this condition.

Inheritance[edit]

Autosomal recessive inheritance, a 25% chance

CPA is thought to be inherited in an autosomal recessive fashion.

Signs and symptoms[edit]

This condition is present at birth in which the lens is missing. In some cases, CPA can be associated with other eye abnormalities including microphthalmia, absence of the iris, anterior segment aplasia, and/or sclerocornea (when the cornea blends with the sclera).

For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed. 80%-99% of people have these symptoms

30%-79% of people have these symptoms

  • Abnormality of vision(Abnormality of sight)
  • Retinal dysplasia
  • Sclerocornea(Hardening of skin and connective tissue)

Diagnosis[edit]

Treatment[edit]

  • Aphakia can be corrected by wearing glasses, contact lenses, artificial lens implantation, or refractive corneal surgeries.
  • Eye with artificial lenses are described as pseudophakic.



NIH genetic and rare disease info[edit]

Congenital primary aphakia is a rare disease.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.